NuvOx Pharma Awarded STTR Grant from NCI for Ultrasound Contrast Agent to Diagnose Pancreatic Cancer

Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer (STTR) grant is a joint development project between NuvOx and Stanford University. The two principal investigators on the project are Drs. Unger and Juergen Willmann, MD, Chief of Body Imaging, Professor of Radiology, Stanford University, School of Medicine.

Read full article here